CN104162057A - Traditional Chinese medicine composition for treating obese polycystic ovarian syndrome and applications thereof - Google Patents
Traditional Chinese medicine composition for treating obese polycystic ovarian syndrome and applications thereof Download PDFInfo
- Publication number
- CN104162057A CN104162057A CN201410421271.4A CN201410421271A CN104162057A CN 104162057 A CN104162057 A CN 104162057A CN 201410421271 A CN201410421271 A CN 201410421271A CN 104162057 A CN104162057 A CN 104162057A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- medicine composition
- rhizoma
- radix
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a traditional Chinese medicine composition for treating obese polycystic ovarian syndrome. The traditional Chinese medicine composition comprises the following bulk drugs: angelica sinensis, radix rehmanniae, radix rehmanniae preparata, rhizoma curculiginis, herba epimedii, grossy privet fruits, folium photiniae, carapax trionycis, salviae miltiorrhizae, cortex moutan, processed rhizoma cyperi, poria cocos, flos caryophylli (decocted later), rhizoma acori graminei, rhizoma atractylodis, bighead atractylodes rhizome, processed rhizoma pinelliae, raw malt, scorch-fried medicated leaven, and raw hawthorn, and in the premenstrual phase, radix bupleuri and herba leonuri are added, in the ovulatory phase, cassia twig and liquidambar formosana hance are added, and in the post menstrual phase, deer horn cornu cervi, amethyst and morinda meat are added. The traditional Chinese medicine composition disclosed by the invention has the advantages that the traditional Chinese medicine composition can tonify kindey and eliminate sputum, and can achieve an effect of increasing the adiponectin level of obese PCOS patients and improve the insulin resistance of the patients. Clinical trials show that the traditional Chinese medicine composition disclosed by the invention has an obvious curative effect, and is worthy of popularization and application.
Description
Technical field
The present invention relates to technical field of Chinese medicines, specifically, is a kind of Chinese medicine composition and application thereof for the treatment of Obesity-type Polycystic Ovary Syndrome.
Background technology
Polycystic ovarian syndrome (poly ovary syndrome, PCOS) is a kind of agnogenic endocrine regulation syndrome.Clinical main manifestations is nothing or the ovulation of rare property, insulin resistant and excessive androgen mass formed by blood stasis.PCOS patient day by day increases, and is day by day threatening the mankind's fertility, brings spirit and physiological double influence to patient, and family, society are also caused to the utmost point factors of instability.
PCOS cause of disease complexity, relates to the many factors such as the local regulation and control of nervus centralis, endocrine, glycolipid fat metabolism and ovary.Study and show at present, insulin resistant plays a part crucial in the pathogenic process of PCOS, and approximately 70% PCOS patient is accompanied with insulin resistant, especially attaches most importance to overweight people.And as new research field---the endocrine function of adipose cell, adiponectin (the Adiponectin of its secretion, the Adipocyte Factor such as APN), not only there is close relationship with insulin resistant, and in the pathogenesis of PCOS, also played pivotal role, become the new viewpoint of PCOS etiological study and treatment.
APN is a kind of endogenous biologically active polypeptide or the protein of adipose cell secretion.It is a kind of insulin sensitivity enhancing hormone (An Insulin-sensitizing Hormone), can improve insulin resistance (Insulin resistance) and the arteriosclerosis of mice; APN is as a kind of insulin hypersensization hormone (An Insulin – sensitizing Hormone), can increase and promote the fatty acid oxidation of Skeletal Muscle Cell and sugar to absorb, obviously strengthen the gluconeogenesis effect of insulin, the sugar that suppresses liver generates, and is the important regulatory factor in the lipid metabolism of body and the regulated and control network of glycaemic homeostasis.In experimental atherosclerosismodel, Plasma Adiponectin Concentration in Patient becomes negative correlativing relation with triglyceride with low density lipoprotein, LDL, becomes positive correlation with high density lipoprotein.The pass of Adipocyte Factor and insulin ties up in zoopery and human research all alleged occurrence fat-islets of langerhans axle.APN has effect of improving insulin resistant.Research shows, people injects APN and can cause the decline of plasma glucose concentration and can improve insulin sensitivity.After morbidity, due to the sustainable existence of insulin resistant, high insulin levels has promoted the formation of PCOS and fat generation.There is research to be negative correlativing relation to APN and insulin resistant, significant for the generation of predict insulin resistance, prompting APN scalable PCOS patient insulin sensitivity.
Modern medicine mainly contains the Therapeutic Method of PCOS: (1) Drug therapy.In common drug, in Diane-35, contained cyproterone acetate is a kind of stronger androgen antagonist preparation, can reduce LH level, increases the concentration of SHBG, obviously improves endocrine regulation, improves LH/FSH ratio.Spironolactone is a kind of aldosterone antagonists, can suppress ovary and adrenal gland's synthetic androgen, with testosterone competition hair follicle androgen receptor, thereby reduces androgen in body, therefore can be used for the excessive androgen mass formed by blood stasis of PCOS.Clomiphene is the choice drug of PCOS induced ovulation, has faint estrogen action, has again anti-androgenic effect, can competitive binding estrogen receptor, reduce intracellular receptor, thereby FSH raise, induced ovulation rate can reach 80%, but pregnancy rate is low, only 40%.The patient of about 20-25% has opposing to this medicine.Promoting sexual gland hormone (HMG) is a kind of glycoprotein hormones, and every containing the each 75IU of LH, FSH.Be applicable to the patient that gonadotropin level is low or endometrium situation is poor.Routine administration pregnancy rate is lower than 30%, and the rate of people having many children is higher than 30%.Gonadotropin releasing hormone (GnPH) and analog thereof are a kind of GnRH nonapeptide analog.Scalable endocrine environment, but pregnancy rate is still not high.(2) operative treatment.Ovarian wedge resection, research is thought to produce androgenic tissue owing to having reduced, and testosterone levels obviously declines, and by negative feedback, FSH secretion is increased, and dominant follicle grows.Ovary tissue reduces thereupon, and inhibin level declines, and FSH raises, and is also that ovarian wedge resection brings out one of reason of ovulation.Shortcoming is to have 10% patient to stick together, and cause the infertile of machinery, and its curative effect is not lasting, and symptomatic recurrence after the several months is seldom used at present.Ovary electric coagulation, is now used to the patient invalid to drug ovulation.Burrow by galvanocautery under peritoneoscope, diathermanous or laser, destroy ovary 15-20 many capsules position, can cause spontaneous ovulation or increase the sensitivity to clomiphene treatment.But still exist, adhesion, curative effect are not lasting, the shortcoming of symptomatic recurrence.
Each scholar of bibliographical information all thinks that the phlegm-damp of suffering from a deficiency of the kidney is the main etiology and pathogenesis of primary disease.Kidney asthenia as the principal aspect.Motherland's medical science thinks, menstruation is the effect of appoint-uterus Reproductive Axis of kidney-menses-punching, is that menses, internal organs, QI and blood, meridians coordinative role are in the physiological phenomenon of uterus."Nei Jing" is said: " kidney qi is contained, menarche, regular menstrual cycle ", and fill and contain as prerequisite taking kidney qi.Fu Qingzhu speech: " through this in kidney ", " going out all kidneys through water ", " female section is through opinion " draws anxiety Tian Shi cloud: " entirely relying executing of kidney water through water ", illustrate that the Material Source of menstruation is originally in kidney.PCOS patient or because of congenital deficiency of kidney-QI, or because damaging spleen kidney the day after tomorrow, often cause stagnation of phlegm-damp punching and appoint, stop up stagnant uterus, upset the physiological action of kidney-menses-punching times-uterus, occurs hypomenorrhea, amenorrhea.Phlegm-dampness constitution person has itself can damage kidney yang, the two reciprocal causation.Phlegm-damp is mark." female section is highly necessary " speech: " its fertile white married woman, the obstructed person of amenorrhea, therefore must be phlegm-damp and adipose membrane be jammed also." clinically, most of PCOS patients have menstrual cycle to delay, hypomenorrhea; body is plentiful or fat in appearance, feeling of oppression over the chest and nausea, and spirit is sleepy; heavy sensation of the body is not well, and to have skin of face oils and fats concurrently more more, and complexion is yellowish and dark; hyperhidrosis and sticky, excessive phlegm saliva in larynx, profuse leukorrhea; matter is rare; light red tongue is fat large, and tongue is greasy in vain, rolling pulse or the heavy specific findings such as slide.Phlegm-damp is traveled round whole body with gas, is detained and produces different pathological changes at different internal organs, patient's obesity of the exuberant skin of phlegm-damp, hirsutism; Phlegm-damp cohesion adipose membrane ovary is the change of many capsules poplar; Phlegm-damp be detained punching appoint uterus menstrual cycle delay, even amenorrhea, these 3 is the typical clinical manifestation of PCOS patient.So it is the main and most important Therapeutic Principle of primary disease that the kidney invigorating is reduced phlegm.
Chinese patent literature CN102205030A discloses a kind of female menstruation-regulating soup of Chinese medicine benefit for the treatment of polycystic ovary syndrome, for the pathogeny of polycystic ovary syndrome, the natural Chinese medicinal herb Rhizoma Dioscoreae of selected tonifying speen and tonifying kidney, vital energy regualting and blood circulation-promoting, drying dampness to eliminate phlegm, Radix Codonopsis, Fructus Lycii, the Rhizoma Atractylodis Macrocephalae, Fructus Psoraleae, Rhizoma Chuanxiong, Radix Salviae Miltiorrhizae, Semen Vaccariae, Herba Leonuri, Radix Platycodonis, Semen Nelumbinis, Poria, Semen Plantaginis are refined and form.Through clinical trial, total effective rate reaches 97.5%, and stable curative effect, and treatment cost is low, non-evident effect; And the generation of dwindling Ovarian Volume and minimizing atretic follicle is also had to obvious curative effects.Chinese patent literature CN102600313A discloses a kind of pharmaceutical composition for the treatment of polycystic ovary syndrome, is formed: stir-baked SQUAMA MANITIS, the Cortex Eucommiae, Semen Cuscutae, Endothelium Corneum Gigeriae Galli, Radix Rehmanniae Preparata, Herba Epimedii, Stigma Croci by following medicine components proportioning; Quality proportioning is: 8 grams of stir-baked SQUAMA MANITISs, 12 grams of the Cortexs Eucommiae, 12 grams of Semen Cuscutae, 8 grams of Endothelium Corneum Gigeriae Galli, 20 grams of Radix Rehmanniae Preparata, 12 grams of Herba Epimedii, 3 grams of Stigma Crocis.Chinese patent application CN101647857 discloses the Chinese medicine composition for the treatment of polycystic ovarian syndrome, is made up of the Radix Astragali, Herba Epimedii, Rhizoma Atractylodis, Poria and Radix Salviae Miltiorrhizae.This Chinese medicine composition has significant curative effect for polycystic ovarian syndrome, and clinical observation has no any toxicity, clinical drug safety.But the Chinese medicine composition for the treatment of Obesity-type Polycystic Ovary Syndrome of the present invention yet there are no report.
Summary of the invention
The object of the invention is for deficiency of the prior art, a kind of Chinese medicine composition for the treatment of Obesity-type Polycystic Ovary Syndrome is provided.
One object more of the present invention is that a kind of application of Chinese medicine composition for the treatment of Obesity-type Polycystic Ovary Syndrome is provided.
For achieving the above object, the technical scheme that the present invention takes is: a kind of Chinese medicine composition for the treatment of Obesity-type Polycystic Ovary Syndrome, described Chinese medicine composition comprises the crude drug of following weight portion: Radix Angelicae Sinensis 14-16 part, Radix Rehmanniae 9-11 part, Radix Rehmanniae Preparata 9-11 part, Rhizoma Curculiginis 14-16 part, Herba Epimedii 14-16 part, Fructus Ligustri Lucidi 28-32 part, Folium Photiniae (Folium Photiniae serrulatae) 9-11 part, Carapax Trionycis 9-11 part, Radix Salviae Miltiorrhizae 9-11 part, Cortex Moutan 9-11 part, Rhizoma Cyperi (processed) 9-11 part, Poria 9-11 part, Flos Caryophylli 2-4 part, Rhizoma Acori Graminei 14-16 part, Rhizoma Atractylodis 14-16 part, Rhizoma Atractylodis Macrocephalae 14-16 part, Rhizoma Pinelliae Preparata 14-16 part, Fructus Hordei Germinatus 55-65 part, burnt six bent 14-16 parts, Fructus Crataegi 14-16 part.
Described Chinese medicine composition also comprises the crude drug of following weight portion: Radix Bupleuri 9-11 part, Herba Leonuri 28-32 part.
Described Chinese medicine composition also comprises the crude drug of following weight portion: Ramulus Cinnamomi 5-7 part, Fructus Liquidambaris 28-32 part.
Described Chinese medicine composition also comprises the crude drug of following weight portion: Cornu Cervi tablet 9-11 part, Fluoritum 28-32 part, Radix Morindae Officinalis 9-11 part.
Described Chinese medicine composition comprises the crude drug of following weight portion: 15 parts of Radix Angelicae Sinensis, 10 parts, the Radix Rehmanniae, 10 parts, Radix Rehmanniae Preparata, 15 parts of Rhizoma Curculiginises, 15 parts of Herba Epimedii, 30 parts of Fructus Ligustri Lucidi, 10 parts of Folium Photiniae (Folium Photiniae serrulatae), 10 parts of Carapax Trionycis, 10 parts of Radix Salviae Miltiorrhizaes, 10 parts of Cortex Moutans, 10 parts of Rhizoma Cyperi (processed), 12 parts, Poria, 3 parts of Flos Caryophyllis, 15 parts of Rhizoma Acori Graminei, 15 parts of Rhizoma Atractylodis, 15 parts of the Rhizoma Atractylodis Macrocephalaes, 15 parts of Rhizoma Pinelliae Preparata, 60 parts of Fructus Hordei Germinatus, 15 parts of burnt six songs, 15 parts of Fructus Crataegi.
Described Chinese medicine composition also comprises the crude drug of following weight portion: 10 parts of Radix Bupleuri, 30 parts of Herba Leonuris.
Described Chinese medicine composition also comprises the crude drug of following weight portion: 6 parts of Ramulus Cinnamomi, 30 parts of Fructus Liquidambaris.
Described Chinese medicine composition also comprises the crude drug of following weight portion: 10 parts of Cornu Cervi tablets, 30 parts of Fluoritum, 10 parts of Radix Morindae Officinaliss.
Described Chinese medicine composition in preparation process after Flos Caryophylli under.
For realizing above-mentioned second object, the technical scheme that the present invention takes is: the application of arbitrary described Chinese medicine composition in the medicine of preparation treatment Obesity-type Polycystic Ovary Syndrome.
The invention has the advantages that:
Chinese medicine composition the kidney invigorating of the present invention is reduced phlegm, Radix Angelicae Sinensis, the Radix Rehmanniae, Radix Rehmanniae Preparata nourishing the blood and yin; Rhizoma Curculiginis, Herba Epimedii, Carapax Trionycis, Fructus Ligustri Lucidi, Folium Photiniae (Folium Photiniae serrulatae), Flos Caryophylli the kidney invigorating warming YANG; Poria enters kidney diuretic, spleen reinforcing and in; Cortex Moutan, Radix Salviae Miltiorrhizae, Rhizoma Cyperi (processed) blood circulation promoting regulates qi dredging collateral; Rhizoma Acori Graminei, Rhizoma Atractylodis, the Rhizoma Atractylodis Macrocephalae, Rhizoma Pinelliae Preparata, Fructus Hordei Germinatus, Jiao Liuqu, Fructus Crataegi eleminating phlegm and freeing channels.Facts have proved, Chinese medicine composition of the present invention can play the effect that increases obese type PCOS adiponectin level and improve this type of patient's insulin resistant, and clinical effectiveness is remarkable, is worthy of popularization.
Detailed description of the invention
Below in conjunction with embodiment, detailed description of the invention provided by the invention is elaborated.
A kind of Chinese medicine composition for the treatment of Obesity-type Polycystic Ovary Syndrome provided by the invention, comprises the crude drug of following weight portion:
Radix Angelicae Sinensis 14-16 part, Radix Rehmanniae 9-11 part, Radix Rehmanniae Preparata 9-11 part, Rhizoma Curculiginis 14-16 part, Herba Epimedii 14-16 part, Fructus Ligustri Lucidi 28-32 part, Folium Photiniae (Folium Photiniae serrulatae) 9-11 part, Carapax Trionycis 9-11 part, Radix Salviae Miltiorrhizae 9-11 part, Cortex Moutan 9-11 part, Rhizoma Cyperi (processed) 9-11 part, Poria 9-11 part, Flos Caryophylli (under rear) 2-4 part, Rhizoma Acori Graminei 14-16 part, Rhizoma Atractylodis 14-16 part, Rhizoma Atractylodis Macrocephalae 14-16 part, Rhizoma Pinelliae Preparata 14-16 part, Fructus Hordei Germinatus 55-65 part, burnt six bent 14-16 parts, Fructus Crataegi 14-16 part.
And add Radix Bupleuri 9-11 part, Herba Leonuri 28-32 part in premenstruum; Add Ramulus Cinnamomi 5-7 part the onset of ovulation, Fructus Liquidambaris 28-32 part; Add Cornu Cervi tablet 9-11 part postmenstruation, Fluoritum 28-32 part, Radix Morindae Officinalis 9-11 part.
embodiment 1 Chinese medicine composition
15 parts of Radix Angelicae Sinensis, 10 parts, the Radix Rehmanniae, 10 parts, Radix Rehmanniae Preparata, 15 parts of Rhizoma Curculiginises, 15 parts of Herba Epimedii, 30 parts of Fructus Ligustri Lucidi, 10 parts of Folium Photiniae (Folium Photiniae serrulatae), 10 parts of Carapax Trionycis, 10 parts of Radix Salviae Miltiorrhizaes, 10 parts of Cortex Moutans, 10 parts of Rhizoma Cyperi (processed), 12 parts, Poria, 3 parts of Flos Caryophyllis (under rear), 15 parts of Rhizoma Acori Graminei, 15 parts of Rhizoma Atractylodis, 15 parts of the Rhizoma Atractylodis Macrocephalaes, 15 parts of Rhizoma Pinelliae Preparata, 60 parts of Fructus Hordei Germinatus, 15 parts of burnt six songs, 15 parts of Fructus Crataegi.
embodiment 2 Chinese medicine compositions
14 parts of Radix Angelicae Sinensis, 11 parts, the Radix Rehmanniae, 9 parts, Radix Rehmanniae Preparata, 14 parts of Rhizoma Curculiginises, 16 parts of Herba Epimedii, 28 parts of Fructus Ligustri Lucidi, 11 parts of Folium Photiniae (Folium Photiniae serrulatae), 9 parts of Carapax Trionycis, 11 parts of Radix Salviae Miltiorrhizaes, 9 parts of Cortex Moutans, 11 parts of Rhizoma Cyperi (processed), 11 parts, Poria, 4 parts of Flos Caryophyllis (under rear), 14 parts of Rhizoma Acori Graminei, 16 parts of Rhizoma Atractylodis, 14 parts of the Rhizoma Atractylodis Macrocephalaes, 16 parts of Rhizoma Pinelliae Preparata, 55 parts of Fructus Hordei Germinatus, 16 parts of burnt six songs, 14 parts of Fructus Crataegi.
embodiment 3 Chinese medicine compositions
16 parts of Radix Angelicae Sinensis, 9 parts, the Radix Rehmanniae, 11 parts, Radix Rehmanniae Preparata, 16 parts of Rhizoma Curculiginises, 14 parts of Herba Epimedii, 32 parts of Fructus Ligustri Lucidi, 9 parts of Folium Photiniae (Folium Photiniae serrulatae), 11 parts of Carapax Trionycis, 9 parts of Radix Salviae Miltiorrhizaes, 11 parts of Cortex Moutans, 9 parts of Rhizoma Cyperi (processed), 13 parts, Poria, 2 parts of Flos Caryophyllis (under rear), 16 parts of Rhizoma Acori Graminei, 14 parts of Rhizoma Atractylodis, 16 parts of the Rhizoma Atractylodis Macrocephalaes, 14 parts of Rhizoma Pinelliae Preparata, 65 parts of Fructus Hordei Germinatus, 14 parts of burnt six songs, 16 parts of Fructus Crataegi.
embodiment 4 is applicable to premenarcheal Chinese medicine composition
15 parts of Radix Angelicae Sinensis, 10 parts, the Radix Rehmanniae, 10 parts, Radix Rehmanniae Preparata, 15 parts of Rhizoma Curculiginises, 15 parts of Herba Epimedii, 30 parts of Fructus Ligustri Lucidi, 10 parts of Folium Photiniae (Folium Photiniae serrulatae), 10 parts of Carapax Trionycis, 10 parts of Radix Salviae Miltiorrhizaes, 10 parts of Cortex Moutans, 10 parts of Rhizoma Cyperi (processed), 12 parts, Poria, 3 parts of Flos Caryophyllis (under rear), 15 parts of Rhizoma Acori Graminei, 15 parts of Rhizoma Atractylodis, 15 parts of the Rhizoma Atractylodis Macrocephalaes, 15 parts of Rhizoma Pinelliae Preparata, 60 parts of Fructus Hordei Germinatus, 15 parts of burnt six songs, 15 parts of Fructus Crataegi, 10 parts of Radix Bupleuri, 30 parts of Herba Leonuris.
embodiment 5 is applicable to premenarcheal Chinese medicine composition
14 parts of Radix Angelicae Sinensis, 11 parts, the Radix Rehmanniae, 9 parts, Radix Rehmanniae Preparata, 14 parts of Rhizoma Curculiginises, 16 parts of Herba Epimedii, 28 parts of Fructus Ligustri Lucidi, 11 parts of Folium Photiniae (Folium Photiniae serrulatae), 9 parts of Carapax Trionycis, 11 parts of Radix Salviae Miltiorrhizaes, 9 parts of Cortex Moutans, 11 parts of Rhizoma Cyperi (processed), 11 parts, Poria, 4 parts of Flos Caryophyllis (under rear), 14 parts of Rhizoma Acori Graminei, 16 parts of Rhizoma Atractylodis, 14 parts of the Rhizoma Atractylodis Macrocephalaes, 16 parts of Rhizoma Pinelliae Preparata, 55 parts of Fructus Hordei Germinatus, 16 parts of burnt six songs, 14 parts of Fructus Crataegi, 11 parts of Radix Bupleuri, 28 parts of Herba Leonuris.
embodiment 6 is applicable to premenarcheal Chinese medicine composition
16 parts of Radix Angelicae Sinensis, 9 parts, the Radix Rehmanniae, 11 parts, Radix Rehmanniae Preparata, 16 parts of Rhizoma Curculiginises, 14 parts of Herba Epimedii, 32 parts of Fructus Ligustri Lucidi, 9 parts of Folium Photiniae (Folium Photiniae serrulatae), 11 parts of Carapax Trionycis, 9 parts of Radix Salviae Miltiorrhizaes, 11 parts of Cortex Moutans, 9 parts of Rhizoma Cyperi (processed), 13 parts, Poria, 2 parts of Flos Caryophyllis (under rear), 16 parts of Rhizoma Acori Graminei, 14 parts of Rhizoma Atractylodis, 16 parts of the Rhizoma Atractylodis Macrocephalaes, 14 parts of Rhizoma Pinelliae Preparata, 65 parts of Fructus Hordei Germinatus, 14 parts of burnt six songs, 16 parts of Fructus Crataegi, 9 parts of Radix Bupleuri, 32 parts of Herba Leonuris.
embodiment 7 is applicable to the Chinese medicine composition of the onset of ovulation
15 parts of Radix Angelicae Sinensis, 10 parts, the Radix Rehmanniae, 10 parts, Radix Rehmanniae Preparata, 15 parts of Rhizoma Curculiginises, 15 parts of Herba Epimedii, 30 parts of Fructus Ligustri Lucidi, 10 parts of Folium Photiniae (Folium Photiniae serrulatae), 10 parts of Carapax Trionycis, 10 parts of Radix Salviae Miltiorrhizaes, 10 parts of Cortex Moutans, 10 parts of Rhizoma Cyperi (processed), 12 parts, Poria, 3 parts of Flos Caryophyllis (under rear), 15 parts of Rhizoma Acori Graminei, 15 parts of Rhizoma Atractylodis, 15 parts of the Rhizoma Atractylodis Macrocephalaes, 15 parts of Rhizoma Pinelliae Preparata, 60 parts of Fructus Hordei Germinatus, 15 parts of burnt six songs, 15 parts of Fructus Crataegi, 6 parts of Ramulus Cinnamomi, 30 parts of Fructus Liquidambaris.
embodiment 8 is applicable to the Chinese medicine composition of the onset of ovulation
14 parts of Radix Angelicae Sinensis, 11 parts, the Radix Rehmanniae, 9 parts, Radix Rehmanniae Preparata, 14 parts of Rhizoma Curculiginises, 16 parts of Herba Epimedii, 28 parts of Fructus Ligustri Lucidi, 11 parts of Folium Photiniae (Folium Photiniae serrulatae), 9 parts of Carapax Trionycis, 11 parts of Radix Salviae Miltiorrhizaes, 9 parts of Cortex Moutans, 11 parts of Rhizoma Cyperi (processed), 11 parts, Poria, 4 parts of Flos Caryophyllis (under rear), 14 parts of Rhizoma Acori Graminei, 16 parts of Rhizoma Atractylodis, 14 parts of the Rhizoma Atractylodis Macrocephalaes, 16 parts of Rhizoma Pinelliae Preparata, 55 parts of Fructus Hordei Germinatus, 16 parts of burnt six songs, 14 parts of Fructus Crataegi, 7 parts of Ramulus Cinnamomi, 28 parts of Fructus Liquidambaris.
embodiment 9 is applicable to the Chinese medicine composition of the onset of ovulation
16 parts of Radix Angelicae Sinensis, 9 parts, the Radix Rehmanniae, 11 parts, Radix Rehmanniae Preparata, 16 parts of Rhizoma Curculiginises, 14 parts of Herba Epimedii, 32 parts of Fructus Ligustri Lucidi, 9 parts of Folium Photiniae (Folium Photiniae serrulatae), 11 parts of Carapax Trionycis, 9 parts of Radix Salviae Miltiorrhizaes, 11 parts of Cortex Moutans, 9 parts of Rhizoma Cyperi (processed), 13 parts, Poria, 2 parts of Flos Caryophyllis (under rear), 16 parts of Rhizoma Acori Graminei, 14 parts of Rhizoma Atractylodis, 16 parts of the Rhizoma Atractylodis Macrocephalaes, 14 parts of Rhizoma Pinelliae Preparata, 65 parts of Fructus Hordei Germinatus, 14 parts of burnt six songs, 16 parts of Fructus Crataegi, 5 parts of Ramulus Cinnamomi, 32 parts of Fructus Liquidambaris.
embodiment 10 is applicable to the Chinese medicine composition of postmenstruation
15 parts of Radix Angelicae Sinensis, 10 parts, the Radix Rehmanniae, 10 parts, Radix Rehmanniae Preparata, 15 parts of Rhizoma Curculiginises, 15 parts of Herba Epimedii, 30 parts of Fructus Ligustri Lucidi, 10 parts of Folium Photiniae (Folium Photiniae serrulatae), 10 parts of Carapax Trionycis, 10 parts of Radix Salviae Miltiorrhizaes, 10 parts of Cortex Moutans, 10 parts of Rhizoma Cyperi (processed), 12 parts, Poria, 3 parts of Flos Caryophyllis (under rear), 15 parts of Rhizoma Acori Graminei, 15 parts of Rhizoma Atractylodis, 15 parts of the Rhizoma Atractylodis Macrocephalaes, 15 parts of Rhizoma Pinelliae Preparata, 60 parts of Fructus Hordei Germinatus, 15 parts of burnt six songs, 15 parts of Fructus Crataegi, 10 parts of Cornu Cervi tablets, 30 parts of Fluoritum, 10 parts of Radix Morindae Officinaliss.
embodiment 11 is applicable to the Chinese medicine composition of postmenstruation
14 parts of Radix Angelicae Sinensis, 11 parts, the Radix Rehmanniae, 9 parts, Radix Rehmanniae Preparata, 14 parts of Rhizoma Curculiginises, 16 parts of Herba Epimedii, 28 parts of Fructus Ligustri Lucidi, 11 parts of Folium Photiniae (Folium Photiniae serrulatae), 9 parts of Carapax Trionycis, 11 parts of Radix Salviae Miltiorrhizaes, 9 parts of Cortex Moutans, 11 parts of Rhizoma Cyperi (processed), 11 parts, Poria, 4 parts of Flos Caryophyllis (under rear), 14 parts of Rhizoma Acori Graminei, 16 parts of Rhizoma Atractylodis, 14 parts of the Rhizoma Atractylodis Macrocephalaes, 16 parts of Rhizoma Pinelliae Preparata, 55 parts of Fructus Hordei Germinatus, 16 parts of burnt six songs, 14 parts of Fructus Crataegi, 11 parts of Cornu Cervi tablets, 32 parts of Fluoritum, 9 parts of Radix Morindae Officinaliss.
embodiment 12 is applicable to the Chinese medicine composition of postmenstruation
16 parts of Radix Angelicae Sinensis, 9 parts, the Radix Rehmanniae, 11 parts, Radix Rehmanniae Preparata, 16 parts of Rhizoma Curculiginises, 14 parts of Herba Epimedii, 32 parts of Fructus Ligustri Lucidi, 9 parts of Folium Photiniae (Folium Photiniae serrulatae), 11 parts of Carapax Trionycis, 9 parts of Radix Salviae Miltiorrhizaes, 11 parts of Cortex Moutans, 9 parts of Rhizoma Cyperi (processed), 13 parts, Poria, 2 parts of Flos Caryophyllis (under rear), 16 parts of Rhizoma Acori Graminei, 14 parts of Rhizoma Atractylodis, 16 parts of the Rhizoma Atractylodis Macrocephalaes, 14 parts of Rhizoma Pinelliae Preparata, 65 parts of Fructus Hordei Germinatus, 14 parts of burnt six songs, 16 parts of Fructus Crataegi, 9 parts of Cornu Cervi tablets, 28 parts of Fluoritum, 11 parts of Radix Morindae Officinaliss.
the preparation of embodiment 13 Chinese medicine composition decoctions
Adopt the manufacture method of Chinese medicine decoction routine, get the arbitrary described Chinese medicine composition of embodiment 1-12 and decoct with water into decoction.
the preparation of embodiment 14 Chinese medicine compositions
Any dosage form that the arbitrary described Chinese medicine composition of embodiment 1-12 is prepared by conventional formulation means, such as granule, capsule, tablet, pill, oral liquid etc.
embodiment 15 clinical trials
1 object of study
1.1 case sources
The all TCM Gynecology medical expert's consultations in the Zhabei District hospital of traditional Chinese hospital and northern station hospital from Chen Danping doctor of 60 routine cases.
1.2 diagnostic criteria
(1) Western medicine diagnose standard: with reference to Rotterdam PCOS diagnosis common recognition in 2003, concrete diagnostic criteria was as follows: 1. rare ovum or anovulation sent a manuscript to the compositor; 2. the clinical and (or) biochemical performance of excessive androgen (performance of clinical excessive androgen mass formed by blood stasis or biochemical analysis prompting androgen raise, and the two meets); 3. ovary polycystic change: ultrasonicly show that a side or bilateral ovaries have the little follicle that 12 diameters are 2-9mm at least, and (or) Ovarian Volume increase >=l0ml; 4. above 3 meet 2 and are diagnosed as PCOS.
(2) tcm diagnosis standard: phlegm-damp card Standards of Chinese Medical Syndrome Differentiation is with reference to " guideline of clinical investigations of new Chinese medicine treatment menoxenia " and according to the 7th edition formulation of China's higher education TCM Major planning teaching material " Gynecology of Chinese Medicine ".
(3) suggestion of the fat guideline of prevention and treatment in the Asian-Pacific area that fat diagnostic criteria proposes according to World Health Organization (WHO) for 2004: Body Mass Index BMI>=24kg/m
2person is fat.
1.3 inclusive criteria
1. within nearly 3 months, not taking hormone medicine, contraceptive or other can affect the medicine of gonadal hormone, serum insulin, blood glucose and blood lipid metabolism; 2. get rid of the excessive androgen mass formed by blood stasis that other diseases causes as congenital adrenal hyperplasia etc.; 3. get rid of cardiovascular disease, diabetes, hepatorenal disease etc.4. have the obese type PCOS patient of insulin resistant.Evaluate insulin resistant degree with stable state type insulin resistance index (HOMA-IR), computational methods are: HOMA-IR=fasting insulin (FINS) (mU/L) × fasting glucose (FPG) (mmol/L)/22.5.HOMA-IR>1 is insulin resistant.
1.4 cases are ended and rejecting standard
(1) in the observation period, can not adhere to therapist, not press therapeutic scheme executor;
(2) took other related drugs therapists;
(3) in treatment, there is the experimenter of serious adverse events/untoward reaction.
1.5 grouping and random method
Conformance with standard case, according to Principle of Statistics, by randomization, is divided into each 30 examples of matched group and treatment group.
2 criterions of therapeutical effect
FPG, FINS, APN measure the 1st menstruation 3-5 days when menstrual cycle 3-5 days or amenorrhea patients B ultrasonic prompting bilateral ovaries is all without dominant follicle (nothing is greater than the follicle of 1cm) before treatment and after drug withdrawal.Gather limosis vein blood 8ml, the centrifugal 10min of 2000r/min, separation of serum ,-20 DEG C of preservations.FINS determining instrument is U.S.'s Beckman full-automatic chemical generation analyser, uses matched reagent box, and lot number is 2284710.The product A U400 of Olympus Corp full automatic biochemical apparatus for FPG, test kit lot number is 0503251.APN determining instrument is the full-automatic enzyme micro-plate reader of Finland MK3, and test kit (being provided by sail bio tech ltd of upper Hisense) is: Rapid Bio Lab Cala-basas.California1.USA product, lot number: 03200601; Measure with ELISA (ELISA).Evaluate insulin resistant degree with stable state type insulin resistance index (HOMA-IR), computational methods are: HOMA-IR=fasting insulin (FINS) (mU/L) × fasting glucose (FPG) (mmol/L)/22.5.
3 Therapeutic Method
Treatment group:
Weight portion weighting raw materials with reference to embodiment 1,4,7,10:
Radix Angelicae Sinensis 15g, Radix Rehmanniae 10g, Radix Rehmanniae Preparata 10g, Rhizoma Curculiginis 15g, Herba Epimedii 15g, Fructus Ligustri Lucidi 30g, Folium Photiniae (Folium Photiniae serrulatae) 10g, Carapax Trionycis 10g, Radix Salviae Miltiorrhizae 10g, Cortex Moutan 10g, Rhizoma Cyperi (processed) 10g, Poria 12g, Flos Caryophylli (under rear) 3g, Rhizoma Acori Graminei 15g, Rhizoma Atractylodis 15g, Rhizoma Atractylodis Macrocephalae 15g, Rhizoma Pinelliae Preparata 15g, Fructus Hordei Germinatus 60g, burnt six bent 15g, Fructus Crataegi 15g.
Premenstruum: add Radix Bupleuri 10g, Herba Leonuri 30g; The onset of ovulation: add Ramulus Cinnamomi 6g, Fructus Liquidambaris 30g; Postmenstruation: add Cornu Cervi tablet 10g, Fluoritum 30g, Radix Morindae Officinalis 10g.
Be decocted in water for oral dose, day potion, 2 times/day, each 200ml, three months is a course for the treatment of.
Matched group:
Poria 15g, Rhizoma Pinelliae Preparata 15g, Pericarpium Citri Reticulatae 9g, Radix Glycyrrhizae Preparata 9g, Rhizoma Atractylodis 15g, Rhizoma Cyperi (processed) 10g, Rhizoma Arisaematis (processed) 15g, Fructus Aurantii 9g, burnt six bent 15g.
Be decocted in water for oral dose, day potion, 2 times/day, each 200ml, three months is a course for the treatment of.
Make in addition individual combination questionnaire by oneself, comprise menstrual history, obsterical history etc., so that overall understanding patient's correlation circumstance.
4 statistical analysis techniques
SPSS 18.0 statistical analysis software processing for data, enumeration data x
2inspection; Between group, mean is relatively checked with t.
5 result of the tests
5.1 clinical datas are collected
By complete method of randomization grouping, every group of each 30 examples of matched group and treatment group.Age 25-35 year, average 28.6 years old.Two groups of patient ages and the comparison for the treatment of front FPG, FINS, APN, HOMA-IR and BMI, no difference of science of statistics (P>0.05), has comparability.Table 1 shows patient age and treats front FSH, LH, E
2, T, BMI statistical result.
Note:
▲with matched group comparison,
p>0.05.
The comparison of 5.2 liang of group indices
After treatment group and treatment of control group, APN all has rising before treating, after treatment, HOMA-IR all has decline before treating, difference has statistical significance (P<0.05), and before and after treatment group treatment, difference has significance (P<0.01).Treatment group curative effect is better than matched group, and difference has statistical significance (P<0.05).As shown in table 2:
Note:
▲with matched group comparison,
p>0.05;
⊿it is relatively front with treatment,
p<0.05;
⊿ ⊿it is relatively front with treatment,
p<0.01; * with matched group comparison,
p<0.05.
5.3 efficacy result
Criterion of therapeutical effect
The each side such as body weight before and after treatment group and treatment of control group, menstrual cycle, biochemical indicator are all improved, the matched group that is better than evident in efficacy for the treatment of group.
Cure: menstrual cycle recovers normal check blood LH/FSH < 2, ultrasound diagnosis: bilateral ovaries normal size, still maintains 3 months above persons of menstrual cycle after drug withdrawal; Effective: menstrual cycle recovers normal, but after drug withdrawal, can not maintain 3 menstrual cycle; Invalid: clinical cardinal symptom, biochemical number, ultrasound diagnosis are unchanged.
Two groups of efficacy results are more as shown in table 3:
Note: with matched group comparison, P < 0.05.
PCOS patient or because of congenital deficiency of kidney-QI, or because damaging spleen kidney the day after tomorrow, often cause stagnation of phlegm-damp punching and appoint, stop up stagnant uterus, upset the physiological action of kidney-menses-punching times-uterus, occurs hypomenorrhea, amenorrhea.Phlegm-dampness constitution person itself can damage again kidney yang, the two reciprocal causation.Kidney asthenia as the principal aspect, phlegm-damp is mark.So it is the main and most important Therapeutic Principle of primary disease that the kidney invigorating is reduced phlegm.Chinese medicine composition of the present invention, Radix Angelicae Sinensis, the Radix Rehmanniae, Radix Rehmanniae Preparata nourishing the blood and yin; Rhizoma Curculiginis, Herba Epimedii, Carapax Trionycis, Fructus Ligustri Lucidi, Folium Photiniae (Folium Photiniae serrulatae), Flos Caryophylli the kidney invigorating warming YANG; Poria enters kidney diuretic, spleen reinforcing and in; Cortex Moutan, Radix Salviae Miltiorrhizae, Rhizoma Cyperi (processed) blood circulation promoting regulates qi dredging collateral; Rhizoma Acori Graminei, Rhizoma Atractylodis, the Rhizoma Atractylodis Macrocephalae, Rhizoma Pinelliae Preparata, Fructus Hordei Germinatus, Jiao Liuqu, Fructus Crataegi eleminating phlegm and freeing channels.Facts have proved, produce effects better than the method for simplification phlegm-damp.To sum up, Chinese medicine composition of the present invention can play the effect that increases obese type PCOS adiponectin level and improve this type of patient's insulin resistant, and clinical effectiveness is remarkable, is worthy of popularization.
The above is only the preferred embodiment of the present invention; it should be pointed out that for those skilled in the art, do not departing under the prerequisite of the inventive method; can also make some improvement and supplement, these improvement and the supplementary protection scope of the present invention that also should be considered as.
Claims (10)
1. treat the Chinese medicine composition of Obesity-type Polycystic Ovary Syndrome for one kind, it is characterized in that, described Chinese medicine composition comprises the crude drug of following weight portion: Radix Angelicae Sinensis 14-16 part, Radix Rehmanniae 9-11 part, Radix Rehmanniae Preparata 9-11 part, Rhizoma Curculiginis 14-16 part, Herba Epimedii 14-16 part, Fructus Ligustri Lucidi 28-32 part, Folium Photiniae (Folium Photiniae serrulatae) 9-11 part, Carapax Trionycis 9-11 part, Radix Salviae Miltiorrhizae 9-11 part, Cortex Moutan 9-11 part, Rhizoma Cyperi (processed) 9-11 part, Poria 9-11 part, Flos Caryophylli 2-4 part, Rhizoma Acori Graminei 14-16 part, Rhizoma Atractylodis 14-16 part, Rhizoma Atractylodis Macrocephalae 14-16 part, Rhizoma Pinelliae Preparata 14-16 part, Fructus Hordei Germinatus 55-65 part, burnt six bent 14-16 parts, Fructus Crataegi 14-16 part.
2. Chinese medicine composition according to claim 1, is characterized in that, described Chinese medicine composition also comprises the crude drug of following weight portion: Radix Bupleuri 9-11 part, Herba Leonuri 28-32 part.
3. Chinese medicine composition according to claim 1, is characterized in that, described Chinese medicine composition also comprises the crude drug of following weight portion: Ramulus Cinnamomi 5-7 part, Fructus Liquidambaris 28-32 part.
4. Chinese medicine composition according to claim 1, is characterized in that, described Chinese medicine composition also comprises the crude drug of following weight portion: Cornu Cervi tablet 9-11 part, Fluoritum 28-32 part, Radix Morindae Officinalis 9-11 part.
5. Chinese medicine composition according to claim 1, is characterized in that, described Chinese medicine composition comprises the crude drug of following weight portion: 15 parts of Radix Angelicae Sinensis, 10 parts, the Radix Rehmanniae, 10 parts, Radix Rehmanniae Preparata, 15 parts of Rhizoma Curculiginises, 15 parts of Herba Epimedii, 30 parts of Fructus Ligustri Lucidi, 10 parts of Folium Photiniae (Folium Photiniae serrulatae), 10 parts of Carapax Trionycis, 10 parts of Radix Salviae Miltiorrhizaes, 10 parts of Cortex Moutans, 10 parts of Rhizoma Cyperi (processed), 12 parts, Poria, 3 parts of Flos Caryophyllis, 15 parts of Rhizoma Acori Graminei, 15 parts of Rhizoma Atractylodis, 15 parts of the Rhizoma Atractylodis Macrocephalaes, 15 parts of Rhizoma Pinelliae Preparata, 60 parts of Fructus Hordei Germinatus, 15 parts of burnt six songs, 15 parts of Fructus Crataegi.
6. Chinese medicine composition according to claim 5, is characterized in that, described Chinese medicine composition also comprises the crude drug of following weight portion: 10 parts of Radix Bupleuri, 30 parts of Herba Leonuris.
7. Chinese medicine composition according to claim 5, is characterized in that, described Chinese medicine composition also comprises the crude drug of following weight portion: 6 parts of Ramulus Cinnamomi, 30 parts of Fructus Liquidambaris.
8. Chinese medicine composition according to claim 5, is characterized in that, described Chinese medicine composition also comprises the crude drug of following weight portion: 10 parts of Cornu Cervi tablets, 30 parts of Fluoritum, 10 parts of Radix Morindae Officinaliss.
9. according to the arbitrary described Chinese medicine composition of claim 1-8, it is characterized in that, described Chinese medicine composition in preparation process after Flos Caryophylli under.
10. the application in the medicine of preparation treatment Obesity-type Polycystic Ovary Syndrome according to the arbitrary described Chinese medicine composition of claim 1-8.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410421271.4A CN104162057A (en) | 2014-08-26 | 2014-08-26 | Traditional Chinese medicine composition for treating obese polycystic ovarian syndrome and applications thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410421271.4A CN104162057A (en) | 2014-08-26 | 2014-08-26 | Traditional Chinese medicine composition for treating obese polycystic ovarian syndrome and applications thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104162057A true CN104162057A (en) | 2014-11-26 |
Family
ID=51906182
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410421271.4A Pending CN104162057A (en) | 2014-08-26 | 2014-08-26 | Traditional Chinese medicine composition for treating obese polycystic ovarian syndrome and applications thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104162057A (en) |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104800780A (en) * | 2015-05-25 | 2015-07-29 | 张卫民 | Traditional Chinese medicine preparation for treating polycystic ovarian syndrome and preparation method of traditional Chinese medicine preparation |
| CN105194193A (en) * | 2015-11-10 | 2015-12-30 | 叶建斌 | Traditional Chinese medicine oral liquid for treating polycystic ovary syndromes and preparation method |
| CN105477249A (en) * | 2015-12-22 | 2016-04-13 | 江苏省中医院 | Traditional Chinese medicinal composition for treating insulin resistance polycystic ovary syndrome |
| CN105596635A (en) * | 2016-01-25 | 2016-05-25 | 青岛云天生物技术有限公司 | Pharmaceutical composition for treating polycystic ovarian syndrome with obesity |
| CN105816617A (en) * | 2016-04-29 | 2016-08-03 | 山东省立医院 | Traditional Chinese medicine composition for treating obesity type polycystic ovarian syndrome |
| CN105853659A (en) * | 2016-06-15 | 2016-08-17 | 山东中医药大学附属医院 | Traditional Chinese medicine composition for treating polycystic ovarian syndrome |
| CN106334060A (en) * | 2016-11-03 | 2017-01-18 | 山东中医药大学附属医院 | Pharmaceutical composition for treating endomorphy type polycystic ovarian syndrome |
| CN108853427A (en) * | 2018-08-02 | 2018-11-23 | 中山大学附属第医院 | A kind of Chinese medicinal formulae for treating overweight/obesity type Stein-Leventhal syndrome |
| CN109045191A (en) * | 2018-11-01 | 2018-12-21 | 上海市北站医院 | A kind of Chinese medicine composition that treating intermenstrual bleeding disease and its application |
| CN113144068A (en) * | 2021-05-12 | 2021-07-23 | 上海市静安区中医医院 | Traditional Chinese medicine composition for treating kidney deficiency type hypomenorrhea and application thereof |
-
2014
- 2014-08-26 CN CN201410421271.4A patent/CN104162057A/en active Pending
Non-Patent Citations (4)
| Title |
|---|
| 朱宝申等: "启宫汤治疗肥胖型多囊卵巢综合征疗效观察", 《中国医药导刊》 * |
| 朱爱兰: "《常用中草药百问百答》", 31 May 2006 * |
| 马红霞等: "中西医结合治疗肥胖型多囊卵巢综合征不孕50例临床观察", 《中医药导报》 * |
| 马静: "补肾化痰法治疗肥胖型多囊卵巢综合征30例", 《山东中医杂志》 * |
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104800780A (en) * | 2015-05-25 | 2015-07-29 | 张卫民 | Traditional Chinese medicine preparation for treating polycystic ovarian syndrome and preparation method of traditional Chinese medicine preparation |
| CN105194193A (en) * | 2015-11-10 | 2015-12-30 | 叶建斌 | Traditional Chinese medicine oral liquid for treating polycystic ovary syndromes and preparation method |
| CN105477249B (en) * | 2015-12-22 | 2019-08-30 | 江苏省中医院 | It is a kind of for treating the Chinese medicine composition of insulin-resistant Stein-Leventhal syndrome |
| CN105477249A (en) * | 2015-12-22 | 2016-04-13 | 江苏省中医院 | Traditional Chinese medicinal composition for treating insulin resistance polycystic ovary syndrome |
| CN105596635A (en) * | 2016-01-25 | 2016-05-25 | 青岛云天生物技术有限公司 | Pharmaceutical composition for treating polycystic ovarian syndrome with obesity |
| CN105816617A (en) * | 2016-04-29 | 2016-08-03 | 山东省立医院 | Traditional Chinese medicine composition for treating obesity type polycystic ovarian syndrome |
| CN105853659A (en) * | 2016-06-15 | 2016-08-17 | 山东中医药大学附属医院 | Traditional Chinese medicine composition for treating polycystic ovarian syndrome |
| CN105853659B (en) * | 2016-06-15 | 2021-06-18 | 山东中医药大学附属医院 | Traditional Chinese medicine composition for treating polycystic ovarian syndrome |
| CN106334060A (en) * | 2016-11-03 | 2017-01-18 | 山东中医药大学附属医院 | Pharmaceutical composition for treating endomorphy type polycystic ovarian syndrome |
| CN108853427A (en) * | 2018-08-02 | 2018-11-23 | 中山大学附属第医院 | A kind of Chinese medicinal formulae for treating overweight/obesity type Stein-Leventhal syndrome |
| CN109045191A (en) * | 2018-11-01 | 2018-12-21 | 上海市北站医院 | A kind of Chinese medicine composition that treating intermenstrual bleeding disease and its application |
| CN109045191B (en) * | 2018-11-01 | 2021-09-03 | 上海市北站医院 | Traditional Chinese medicine composition for treating intermenstrual bleeding diseases and application thereof |
| CN113144068A (en) * | 2021-05-12 | 2021-07-23 | 上海市静安区中医医院 | Traditional Chinese medicine composition for treating kidney deficiency type hypomenorrhea and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104162057A (en) | Traditional Chinese medicine composition for treating obese polycystic ovarian syndrome and applications thereof | |
| Liu et al. | Chinese herbal medicines for treating osteoporosis | |
| CN103463568B (en) | Traditional Chinese medicine for treating coronary heart disease | |
| CN105031559B (en) | It is a kind of to treat the Chinese medicine for causing infertility by Stein-Leventhal syndrome | |
| CN103751529A (en) | Traditional Chinese medicine composition for treating female postmenopausal osteoporosis and preparation method thereof | |
| CN103341004A (en) | Chinese medicine composition for treating delayed menstrual cycle | |
| CN101879291A (en) | Depression relieving and tranquilizing mixed decoction (powder) and pills | |
| CN103585378A (en) | A Chinese medicinal composition for treating female infertility, and its preparation method | |
| CN101947300B (en) | Traditional Chinese medicinal composition for treating liver diseases, preparation method thereof and use thereof | |
| CN104922543A (en) | Medicine composite for treating amenorrhea and preparation method thereof | |
| CN103550476B (en) | A kind of pharmaceutical composition for the treatment of postmenopausal osteoporosis and preparation method thereof | |
| CN109528980B (en) | Traditional Chinese medicine composition for treating ovarian reserve function decline disease and pharmaceutical application thereof | |
| CN105012720A (en) | Traditional Chinese medicine composition for treating osteopathy | |
| CN106362104A (en) | Pharmaceutical composition for treating polycystic ovary syndrome in adolescence | |
| CN101537159B (en) | Traditional Chinese medicine composition and preparation method and application thereof | |
| CN102441111B (en) | Chinese patent medicine used for treating infertility, and preparation method thereof | |
| CN103301353B (en) | Pharmaceutical composition for treating atrophic vaginitis | |
| CN105250556A (en) | Traditional Chinese medicine drug for treating polycystic ovarian syndrome | |
| CN105497262A (en) | Medicine composition for treating liver-yin and kidney-yin deficiency type polycystic ovarian syndrome | |
| CN110237161A (en) | Drug and its preparation method and application for treating menopausal syndrome | |
| CN105250754B (en) | It is a kind of alleviate menopause symptom Chinese medicine composition and its application | |
| CN110141656A (en) | A kind of Fuke Tiaojing blood-nourishing Chinese medicine composition and preparation method thereof | |
| CN103690925A (en) | Traditional Chinese medicinal composition for treating amenorrhea | |
| CN108635457A (en) | A kind of Chinese medicine composition and the preparation method and application thereof for treating constipation | |
| CN1065765C (en) | Chinese medicine for curing female endocrinopathy and its preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| AD01 | Patent right deemed abandoned |
Effective date of abandoning: 20171103 |
|
| AD01 | Patent right deemed abandoned |